Skip to main content
ScholarsBetaWeill Cornell Medicine

Highlights

  1. 1
    Pituitary · 2022
    SSSara StraussCDC Douglas PhillipsJLJoshua LantosRRRohan RamakrishnaGAGeorgiana Alina Dobri
    PMID: 36462067DOISenior author9 citations

Publications

28 publications

Funding

1 grant

Active

1 grant
  • Co-I
    Somatostatin Receptor 2 Expression in Pituitary Neuroendocrine Tumors as a Basis for PET/MRI guided Subtype Stratification and Radiotherapy Planning
    National Cancer Institute · 2025–2027
    R21CA289111-01A1

Clinical research

5 studies

Active

2 studies
  • PI
    A Multi-national, Multi-centre, Prospective, Single-arm, Observational, Non-interventional Post-authorisation Safety Study to Investigate Long-term Safety of Sogroya® (Somapacitan) in Adults With Growth Hormone Deficiency (AGHD) Under Routine Clinical Practice
    Novo Nordisk Pharmaceuticals, Inc. · OPEN TO ACCRUAL (as of 2025)
    Adult Growth Hormone Deficiency
    NCT05718570
  • PI
    An Open-Label Extension Study of the Safety of Relacorilant (CORT125134) in the Treatment of the Signs and Symptoms of Endogenous Cushing Syndrome
    PHASE2 · Corcept Therapeutics Incorporated · OPEN TO ACCRUAL (as of 2021)
    Cushing Syndrome
    NCT03604198
Completed & closed trials (3)
  • PI
    A Multicenter, Open-Label, Extension Trial to Investigate Long Term Efficacy and Safety of Lonapegsomatropin in Adults With Growth Hormone Deficiency
    PHASE3 · Ascendis Pharma Endocrinology Division A/S · IRB STUDY CLOSURE (as of 2025)
    Adult Growth Hormone Deficiency; Endocrine System Diseases; Hormone Deficiency
    NCT05171855
  • PI
    Glucocorticoid Receptor Antagonism in the Treatment of Hypercortisolism in Patients With Cortisol-Secreting Adrenal Adenomas or Hyperplasia (GRADIENT): A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Relacorilant
    PHASE3 · Corcept Therapeutics Incorporated · IRB STUDY CLOSURE (as of 2025)
    Hypercortisolism
    NCT04308590
  • PI
    foresiGHt: A Multicenter, Randomized, Parallel-arm, Placebo-controlled (Double- Blind) and Active-controlled (Open-label) Trial to Compare the Efficacy and Safety of Once-weekly Lonapegsomatropin With Placebo and a Daily Somatropin Product in Adults With Growth Hormone Deficiency
    PHASE3 · Ascendis Pharma Endocrinology Division A/S · IRB STUDY CLOSURE (as of 2024)
    Growth Hormone Deficiency; Endocrine System Diseases; Hormone Deficiency
    NCT04615273

External relationships

Advisory/Scientific Board Member

Camurus AB · Chiesi Pharmaceuticals · Novo Nordisk Pharmaceuticals, Inc. · Xeris Biopharma Holdings, Inc.